These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24914822)

  • 1. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies.
    Zacharioudakis IM; Ziakas PD; Mylonakis E
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1650-4. PubMed ID: 24914822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
    Kamboj M; Xiao K; Kaltsas A; Huang YT; Sun J; Chung D; Wu S; Sheahan A; Sepkowitz K; Jakubowski AA; Papanicolaou G
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1626-33. PubMed ID: 24973628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
    Willems L; Porcher R; Lafaurie M; Casin I; Robin M; Xhaard A; Andreoli AL; Rodriguez-Otero P; Dhedin N; Socié G; Ribaud P; Peffault de Latour R
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1295-301. PubMed ID: 22387347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients.
    Scardina TL; Kang Martinez E; Balasubramanian N; Fox-Geiman M; Smith SE; Parada JP
    Pharmacotherapy; 2017 Apr; 37(4):420-428. PubMed ID: 28226419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
    Aldrete SD; Kraft CS; Magee MJ; Chan A; Hutcherson D; Langston AA; Greenwell BI; Burd EM; Friedman-Moraco R
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada.
    Lavallée C; Labbé AC; Talbot JD; Alonso CD; Marr KA; Cohen S; Laverdière M; Dufresne SF
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
    Agha A; Sehgal A; Lim MJ; Weber D; Hou JZ; Farah R; Raptis A; Im A; Dorritie K; Marks S; Agha M; Lim SH
    Am J Hematol; 2016 Mar; 91(3):291-4. PubMed ID: 26661725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation.
    Akahoshi Y; Kimura S; Nakano H; Harada N; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Nakasone H; Kikuchi M; Yamazaki R; Kanda J; Kako S; Nishida J; Kanda Y
    Clin Transplant; 2016 Jun; 30(6):703-8. PubMed ID: 27019071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation.
    Bruminhent J; Wang ZX; Hu C; Wagner J; Sunday R; Bobik B; Hegarty S; Keith S; Alpdogan S; Carabasi M; Filicko-O'Hara J; Flomenberg N; Kasner M; Outschoorn UM; Weiss M; Flomenberg P
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1329-34. PubMed ID: 24792871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of
    Luo Y; Zhang S; Shang H; Cui W; Wang Q; Zhu B
    Front Cell Infect Microbiol; 2022; 12():801475. PubMed ID: 35265530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.
    Salamonowicz M; Ociepa T; Frączkiewicz J; Szmydki-Baran A; Matysiak M; Czyżewski K; Wysocki M; Gałązka P; Zalas-Więcek P; Irga-Jaworska N; Drożyńska E; Zając-Spychała O; Wachowiak J; Gryniewicz-Kwiatkowska O; Czajńska-Deptuła A; Dembowska-Bagińska B; Chełmecka-Wiktorczyk L; Balwierz W; Bartnik M; Zielezińska K; Urasiński T; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Pierlejewski F; Młynarski W; Gamrot-Pyka Z; Woszczyk M; Małas Z; Badowska W; Urbanek-Dądela A; Karolczyk G; Stolpa W; Sobol-Milejska G; Zaucha-Prażmo A; Kowalczyk J; Goździk J; Gorczyńska E; Jermakow K; Król A; Chybicka A; Ussowicz M; Kałwak K; Styczyński J
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1805-1812. PubMed ID: 29978303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis.
    Vehreschild MJ; Weitershagen D; Biehl LM; Tacke D; Waldschmidt D; Töx U; Wisplinghoff H; Von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):823-8. PubMed ID: 24607558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients.
    Chopra T; Alangaden GJ; Chandrasekar P
    Expert Rev Anti Infect Ther; 2010 Oct; 8(10):1113-9. PubMed ID: 20954878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.
    Mani S; Rybicki L; Jagadeesh D; Mossad SB
    Bone Marrow Transplant; 2016 May; 51(5):713-7. PubMed ID: 26726944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea.
    Tomblyn M; Gordon L; Singhal S; Tallman M; Williams S; Winter J; Mehta J
    Bone Marrow Transplant; 2002 Oct; 30(8):517-9. PubMed ID: 12379891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation.
    Kinnebrew MA; Lee YJ; Jenq RR; Lipuma L; Littmann ER; Gobourne A; No D; van den Brink M; Pamer EG; Taur Y
    PLoS One; 2014; 9(3):e90158. PubMed ID: 24662889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridioides difficile colonization and infection in patients admitted for a first autologous transplantation: Incidence, risk factors, and patient outcomes.
    Ford CD; Lopansri BK; Coombs J; Webb BJ; Nguyen A; Asch J; Hoda D
    Clin Transplant; 2019 Nov; 33(11):e13712. PubMed ID: 31532030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.
    Krishna SG; Zhao W; Apewokin SK; Krishna K; Chepyala P; Anaissie EJ
    Transpl Infect Dis; 2013 Oct; 15(5):493-501. PubMed ID: 24034141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.